Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (vol 70, pg 215, 2010)

被引：0
|
作者：
Garnock-Jones, K. P.
Keating, G. M.
Scott, L. J.
机构：
来源：
DRUGS | 2011年 / 71卷 / 12期
关键词：
D O I：
10.2165/11596220-000000000-00000
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1578 / 1578
页数：1
相关论文
共 50 条
  • [1] Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    DRUGS, 2010, 70 (02) : 215 - 239
  • [2] Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer
    KP Garnock-Jones
    GM Keating
    LJ Scott
    Drugs, 2011, 71 : 1578 - 1578
  • [3] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    BIODRUGS, 2010, 24 (03) : 207 - 209
  • [4] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
    Karly P. Garnock-Jones
    Gillian M. Keating
    Lesley J. Scott
    BioDrugs, 2010, 24 : 207 - 209
  • [5] TrastuzumabA Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer
    Karly P. Garnock-Jones
    Gillian M. Keating
    Lesley J. Scott
    Drugs, 2010, 70 : 215 - 239
  • [6] Clinical and echocardiographic predictors of early trastuzumab cardiotoxicity in adjuvant treatment of positive human epidermal growth factor receptor type 2 (HER2) breast cancer
    Piotrowski, G.
    Gawor, R.
    Strzelecki, P.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1063 - 1063
  • [7] De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.
    Goldvaser, Hadar
    Yasmin, Korzets Ceder
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
    Freedman, Rachel A.
    Hughes, Melissa E.
    Ottesen, Rebecca A.
    Weeks, Jane C.
    He, Yulei
    Wong, Yu-Ning
    Theriault, Richard
    Keating, Nancy L.
    CANCER, 2013, 119 (04) : 839 - 846
  • [9] Tailored duration of adjuvant trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Zhou, Zhi-Rui
    Shao, Zhi-Ming
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
12345